Ebola Virus Vaccine Market - By Strain Type (Vesicular Stomatitis Virus (rVSV), Adeno Virus Serotype - 26), End-use (Hospitals, Clinics, Ambulatory Surgical Centers) & Forecast 2023 - 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationEbola Virus Vaccine Market - By Strain Type (Vesicular Stomatitis Virus (rVSV), Adeno Virus Serotype - 26), End-use (Hospitals, Clinics, Ambulatory Surgical Centers) & Forecast 2023 - 2032
Ebola Virus Vaccine Market Size
Ebola Virus Vaccine Market size accounted for USD 4.4 million in 2022 and is estimated to grow at 32.6% to reach USD 71 million by 2032. The growing incidence of zoonotic diseases across the globe will drive the market expansion.
For instance, in 2020, according to the World Health Organization (WHO), around 60% of known infectious diseases and over 75% of emerging infectious diseases are zoonotic in origin. Thus, increasing incidence of zoonotic disease such as Ebola and zoonotic influenza among others is expected to boost the market progression. Furthermore, increasing public health initiatives to prevent and control Ebola outbreaks have resulted in increased investments in vaccine development and procurement, thereby fostering the market trends.
Ebola virus vaccines are developed using various approaches, such as viral vectors, recombinant proteins and DNA-based platforms. These vaccines typically contain components of the Ebola virus such as viral proteins or genetic material that are modified or attenuated to be safe for use in humans. When administered, the vaccine triggers an immune response that produces specific antibodies and cellular immunity, providing protection against the Ebola virus.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Ebola Virus Vaccine Market Size in 2022 | USD 4.4 Million |
| Forecast Period | 2022 |
| Forecast Period 2022 CAGR | 32.6% |
| 2022 Value Projection | USD 71 Million |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 70 |
| Tables, Charts & Figures | 91 |
| Segments covered | Strain Type, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the Ebola virus vaccine market. Increasing number of COVID-19 cases lead to a shift in focus from developing Ebola vaccines to COVID-19 vaccines. The COVID-19 pandemic and emergence of new variants of the SARS-CoV-2 virus have created the urge of developing COVID-19 vaccine to limit and curb the spread of COVID-19 infection. Thus, owing to such aforementioned factor, a temporary shift shit from addressing Ebola vaccine development was observed, thereby potentially impacted the progress and effectiveness of Ebola vaccine development programs during the period.
Ebola Virus Vaccine Market Trends
As scientists and researchers race to find effective ways to fight Ebola, the market for Ebola vaccines is expected to surge. Big-name drug makers and research centers are pouring money into developing new vaccines to protect people from this deadly virus. For example, in 2021, Bavarian Nordic and Johnson & Johnson teamed up to donate up to 200,000 doses of Johnson & Johnson's Ebola vaccine to the World Health Organization (WHO). This is just one example of how companies and organizations are stepping up to help stop the spread of Ebola, particularly in West Africa. And as the demand for these vaccines continues to grow, so will the market for them.
Ebola Virus Vaccine Market Restraint
Getting Ebola vaccines approved by regulators is no walk in the park. The rules are super strict, which slows down the process of bringing new vaccines to people who need them. It's also hard for smaller companies to enter the market because the approval process takes a lot of time and money. To get vaccines approved, companies have to do a lot of testing to make sure they're safe and effective. They also have to follow strict rules when it comes to making and selling the vaccines. This can be a challenge for small companies that don't have the same resources as big companies. All of these regulatory hurdles make it harder for new vaccines to reach the market. This limits competition, and it can prevent people from getting the vaccines they need to protect themselves from Ebola. As a result, the market for Ebola vaccines can't grow as quickly as it could if the approval process were easier.
Ebola Virus Vaccine Market Analysis
When it comes to Ebola vaccines, there are two main typesthose made using a virus called rVSV (vesicular stomatitis virus) and those made using a virus called Ad26 (adenovirus stereotype - 26). In 2022, the rVSV vaccines were the boss, taking up over half the market. And it looks like they'll keep growing strong in the years to come. These rVSV vaccines are pretty cool because they use the rVSV virus as a messenger to deliver pieces of the Ebola virus into our bodies. This tricks our immune systems into thinking the real Ebola virus is attacking, so they can learn to fight it off in the future. One of the advantages of using rVSV is that it can be made quickly and easily. This makes it great for dealing with outbreaks, where time is of the essence. Plus, it can be made in large quantities, so there's enough to go around. Another bonus is that the rVSV virus has been used safely in other vaccines, which makes it a good choice for Ebola vaccines too. So, all these factors have helped make rVSV vaccines the preferred choice for fighting the Ebola virus.
When it comes to Ebola virus vaccines, they can be used in different places, such as hospitals, clinics, and surgery centers. In 2022, hospitals were the biggest users, bringing in about $1.6 million. Hospitals and clinics have a lot of experienced medical staff and fancy equipment, which has helped them grow. They also make it easier for people to get vaccinated when they go in for other medical care. Hospitals and clinics also have good storage facilities and a well-thought-out system for giving out vaccines. This helps to prevent shortages and waste. So, these reasons are likely to keep driving the growth of the Ebola virus vaccine market.
In 2022, the U.S. market for Ebola vaccines grabbed more than half (52.3%) of the total market. And it's expected to keep growing steadily over the next few years. Why? Well, the number of zoonotic diseases (those that spread from animals to humans) is going up. And so is the use of cutting-edge medical tech. This is helping to push the market growth in the U.S. Plus, the U.S. has a strong healthcare system, with big players in the market and lots of research going on. This is also helping to boost the development of Ebola vaccines. And with more and more people wanting to protect themselves against preventable diseases, governments are spending more money to raise awareness about vaccinations and stop outbreaks. All of this is giving the Ebola vaccine market in North America a big boost.
Ebola Virus Vaccine Market Share
Major market players operating in the Ebola virus vaccine industry include
- Merck & Co., Inc
- Johnson & Johnson
- Bavarian Nordic
- GlaxoSmithKline plc
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.
Ebola Virus Vaccine Industry News
- In July 2020, Johnson & Johnson received European Commission approval for Ebola vaccine regimen for the prevention of Ebola Virus Disease. This strategy approval enables the company to collaborate with World Health Organization (WHO) on vaccine pre-qualification that helped in accelerating registration of its preventive Ebola vaccine regimen in African countries, thereby consolidating its market position.
- In December 2019, Merck & Co., Inc. received FDA approval for ERVEBO (Ebola Zaire Vaccine, Live) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. This product approval helped the company to enhance its product offerings and consolidate its market presence in Ebola vaccine industry.
The Ebola virus vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Strain Type
- Vesicular Stomatitis Virus (rVSV)
- Adeno Virus Serotype - 26
End-use
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Europe
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Africa
- The Democratic Republic of the Congo (DRC)
- Burundi
- Ghana
- Zambia
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy